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Abstract
Objective The objective of this study is to test if patients’
health-related quality of life (HRQoL) declines after pros-
tate biopsy to detect Pca, and after subsequent treatment
decision-making in case Pca is confirmed, and to test
whether personality state and traits are associated with
these potential changes in HRQoL.
Methods Patients who were scheduled for prostate biopsy to
detect Pca (N = 377) filled out a baseline questionnaire about
HRQoL (EORTC QLQ-C30 and PR25), Bbig five^ personal-
ity traits (BFI-10), optimism (LOT-r), and self-efficacy
(Decision Self-efficacy Scale) (t0). Patients with confirmed
Pca (N = 126) filled out a follow-up questionnaire on
HRQoL within 2 weeks after treatment was chosen but had
not yet started (t1).
Results HRQoL declined between t0 and t1, reflected in
impaired role and cognitive functioning, and elevated fa-
tigue, constipation, and prostate-specific symptoms.
Sexual activity and functioning improved. Baseline
HRQoL scores were unrelated to the selection of a partic-
ular treatment, but for patients who chose a curative treat-
ment, post-decision HRQoL showed a greater decline
compared to patients who chose active surveillance.
Optimism was associated with HRQoL at baseline; deci-
sional self-efficacy was positively associated with
HRQoL at follow-up. No associations between HRQoL
and the Bbig five^ personality traits were found.
Conclusion Patients who have undergone prostate biopsy and
treatment decision-making for Pca experience a decline in
HRQoL. Choosing treatment with a curative intent was asso-
ciated with greater decline in HRQoL. Interventions aimed at
optimism and decision self-efficacy could be helpful to reduce
HRQoL impairment around the time of prostate biopsy and
treatment decision-making.
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Background
An aging population and increased use of prostate can-
cer (Pca) screening contribute to a growth in Pca detec-
tion in The Netherlands and other Western countries
[1–3]. When Pca is suspected, patients undergo prostate
biopsy [4]. In The Netherlands only, at least 25,000
Dutch men undergo this procedure every year, resulting
in approximately 10,000 Pca diagnoses (Netherlands
Cancer Registry, 2015) [5]. The largest proportion of
Pca diagnoses consist of localized cancer (stage I or
II), for which surgery, radiotherapy (either brachy or
external beam), and active surveillance (AS) are seen
as equally acceptable treatments [4, 6]. However, ad-
verse effects from treatment can impair patients’
health-related quali ty of l ife (HRQoL) [7–10].
Common side effects from treatments with curative in-
tent (surgery, radiotherapy) include sexual, urinary, and
bowel-related complaints [9, 11], while AS can increase
anxiety symptoms due to postponing treatment [12, 13].
Therefore, impact on HRQoL is an important factor
when considering treatment options [14–16].
Changes in HRQoL after Pca treatment are well de-
scribed and generally consist of a major decline in
HRQoL in the first 1–2 years after treatment [9,
17–19]. Besides the consequences of treatment, changes
in HRQoL are related to psychological factors.
Optimism and self-efficacy are associated with better
HRQoL outcomes, while anxiety, depression, and per-
sonality traits (e.g., neuroticism, distress) are associated
with worse HRQoL outcomes [20–23]. However, most
of these studies measured HRQoL from diagnosis on-
wards, lacking a pre-diagnosis baseline to also capture
the psychological burden from prostate biopsy, receiving
a Pca diagnosis, and treatment selection. Studies that
did take a pre-diagnosis baseline focused on aspecific
(older) patient population and did not measure immedi-
ately before and after diagnosis [24, 25].
To increase our understanding about the impact of
Pca on HRQoL, including receiving a Pca diagnosis
and choosing treatment, this study measured HRQoL
pre-biopsy and post-treatment decision-making. Our hy-
pothesis was that a significant decline in HRQoL would
already appear prior to treatment onset from the psycho-
logical burden of diagnosis and treatment decision-mak-
ing. Moreover, we expected changes in HRQoL would
be associated with psychological factors (personality
traits, optimism, and self-efficacy).
Methods
Participants and recruitment
Between January 2013 and May 2014, ten Dutch hospitals
participated in this study and recruited 388 patients who were
scheduled for a first prostate biopsy due to suspected Pca
(Mage = 66.5, SD = 6.6; Fig. 1). A host hoc power analysis
revealed that this sample size was sufficient to achieve a pow-
er of 0.80 for detecting differences with an effect size from
Cohen’s d = 0.2 (with alpha 0.05). During consultation, pa-
tients were informed that the goal of the study was to investi-
gate quality of care in prostate examination and quality of life
of patients undergoing this procedure. Together with an infor-
mation letter, patients received the first questionnaire (t0) on
paper and a pre-stamped envelope to return the questionnaire.
Follow-up questionnaires were sent to patients whose biopsy
result confirmed Pca. These patients received this second
questionnaire and a pre-stamped envelope at their home ad-
dress within 2 weeks after treatment decision-making (t1).
Diagnosis and the moment of treatment decision-making were
monitored for all included patients from their (electronic)
medical record. After review of the study protocol, the medi-
cal ethics review board of the initiating hospital waived the
need for formal ethical approval (reference 2012.103) and all
participating hospitals approved conducting the study. All pa-
tients signed an informed consent.
Questionnaires
Demographics and clinical data
Participants were asked to indicate their age, education, mar-
ital status, last known prostate-specific antigen (PSA) level,
and choice of treatment. PSA levels were asked at both t0 and
t1 to control for the possibility that treatment had already taken
place before completing the t1 questionnaire.
Health-related quality of life
HRQoL was measured with the Dutch version of the EORTC
QLQ-C30 questionnaire, which assesses functional HRQoL
aspects (physical, role, cognitive, emotional, and social func-
tioning and global health) and symptoms common for cancer
patients (fatigue, nausea, pain, dyspnea, sleep disturbance,
appetite loss, constipation, diarrhea, and financial impact)
[26]. The prostate cancer-specific EORTC QLQ-PR25 mod-
ule was added to assess prostate cancer-specific (urinary, bow-
el, and hormonal) symptoms and (sexual) functioning [27].
Scale reliability was low for the bowel and hormonal symp-
toms, and sexual activity subscale (alpha’s 0.50–0.60), and
adequate (alpha ≥ 0.70) for all other subscales. Similar scale
reliability scores have been found earlier [27].
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Psychological factors
As possible moderating variables, three measures for individ-
ual differences measures were included. First, the Big Five
Inventory-10 (BFI-10) was included to measure extraversion,
agreeableness, conscientiousness, neuroticism, and openness,
also known as the Bbig five^ personality traits [28]. The BFI-
10 was included in t0. With only two items per trait, low
reliability scores were found (α < 0.50), which is common
for this scale [29]. A subsequent confirmatory factor analysis
confirmed five underlying factors, with each set of two items
per trait yielding highest factor loadings.
Secondly, dispositional optimism, a generalized expecta-
tion that good things will happen, was assessed with the Life
Orientation Test-Revised (LOT-R) [30]. Some minor textual
adjustments were made to an existing and previously validat-
ed Dutch version of the LOT-R [31]. Scale reliability was
sufficient (α = 0.67).
Thirdly, the Decision Self-Efficacy Scale was used as a
subjective measure of the perceived ability to make a
healthcare decision [32]. Rather than focusing on one specific
decision, the goal of this scale was to measure feelings of self-
confidence in a healthcare setting. The scale was included at t0
to measure a person’s baseline decisional self-efficacy before
the distress from diagnosis. In the absence of an existing and
validated Dutch version of this scale, a forward-backward
translation was made by two researchers and the result was
evaluated and consented on by two other researchers who
were not involved to the translation. Scale reliability was good
(α = 0.85).
Statistical analysis
Descriptive statistics are presented as means and stan-
dard deviations (SD) for continuous variables and as
frequencies and percentages for categorical variables.
Mean HRQoL scores at t0 were compared to the scores
obtained at t1 using paired-samples t tests. The associ-
ation between personality traits and HRQoL scores was
assessed using bivariate correlation analyses (Pearson’s).
Linear regression modeling was carried out with global
health as dependent variable and personality character-
istics as independent variables, controlling for age, edu-
cation, PSA levels, and diagnosis (dummy variable; for
t0 only). All analyses were performed using SPSS ver-
sion 22.0 (Statistical Package for Social Sciences,
Chicago, IL, USA). p values < 0.05 were considered
statistically significant.
Results
Three hundred and 88 patients gave informed consent of
which 377 patients completed the first questionnaire (t0, re-
sponse rate 97.2%). All patients whose biopsy confirmed Pca
(n = 126 patients, 32%) received the follow-up questionnaire
(t1, response rate 63%) (Fig. 1). There were no statistically
significant differences in demographics between patients with
cancer and patients without cancer at t0, between responders
at t0 and t1, or between responders and non-responders at t1.
Patient demographics are presented in Table 1.
Health-related quality of life
At the pre-biopsy baseline (t0), HRQoL did not differ between
patients whose biopsy result confirmed Pca and patients with a
negative biopsy result (Table 2). After receiving diagnosis and
treatment decision-making (t1), patients reported worse role
and cognitive functioning and more symptoms (fatigue, con-
stipation, urinary, bowel, and hormonal). Sexual activity and
functioning improved after treatment were chosen (all with
p < 0.05; Table 2).
388 patients scheduled for prostate biopsy consented to participate
377 Patients filled out first 
questionnaire (97.2%)
11 Patients did not return first 
questionnaire (2.8%)
254 patients with 
negative biopsy 
result
123 patients 
diagnosed with Pca
3 patients 
diagnosed with Pca
8 patients with 
negative biopsy 
result
126 patients received follow-up 
questionnaire after diagnosis
80 patients filled out follow-up 
questionnaire (63.5%)
46 patients did not return follow-up 
questionnaire (36.5%)
Fig. 1 Patient flow
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Treatment choice
In case Pca was detected, symptoms and functioning reported
prior to biopsy (t0) were not associated with selection of a
particular treatment. At the time point after treatment
decision-making (t1), men who chose a curative treatment
reported reduced functioning and more symptoms compared
to men who selected AS (Table 3). No associations were
found between treatment choice and personality characteris-
tics (data not shown).
Psychological variables
Prior to biopsy (t0), optimism was a significant predictor for
global health (B = .31, p < .001). After receiving diagnosis
and treatment decision-making (t1), a positive association was
found between global health and decisional self-efficacy
(B = 0.29, p = .04). Of the big five traits, extraversion
(B = 0.14, p = .03) and neuroticism (B = − 0.17, p = .01) were
significant predictors for global health at t0; no relations were
found at t1.
Discussion
This study investigated the HRQoL impacts of undergoing
prostate biopsy, receiving Pca diagnosis, and choosing treat-
ment. Prior to prostate biopsy, when Pca is suspected but not
yet confirmed, HRQoL was similar between patients who
were later confirmed to have Pca and patients without Pca.
When a Pca diagnosis was received, and treatment was chosen
but had not yet started, patients reported more symptoms and
reduced functioning compared to the pre-biopsy baseline.
HRQoL at baseline did not predict treatment choice, but pa-
tients who chose a curative treatment instead of AS reported
more symptoms and reduced functioning compared to patients
who chose AS. Overall global health at baseline was related to
optimism; after diagnosis and treatment selection, an associa-
tion with decisional self-efficacy was found.
HRQoL outcomes
Differences in HRQoL between patients who selected
curative treatment over AS are not surprising. Men eli-
gible for AS could be expected to be in a more favorable
condition compared to men who need (immediate) cura-
tive treatment [33]. However, it is remarkable that most
HRQoL differences were not present in our sample at
baseline but were only reported after diagnosis and treat-
ment selection. Moreover, the highest level of urinary
symptoms at t0 was reported by men who later selected
AS, while after the treatment decision was made, most
symptoms were reported by men who selected a curative
treatment. Therefore, changes in HRQoL appear to be
influenced by the impact of diagnosis and treatment de-
cision-making, rather than by changes in the patient’s
physical condition. Possibly, the Pca diagnosis made
men more aware of their symptoms and led them to
attribute their overall condition more to their disease.
Increased symptom burden and impaired functioning at
t1 could also be explained by cognitive dissonance re-
duction [34]; consequently of a finalized treatment deci-
sion, men could be motivated to justify this decision as
being the right one. This could have resulted in a revised
HRQoL evaluation at t1 to make it consonant with the
characteristics that would fit to the selected treatment
[35, 36]. If biopsy itself caused a decline in HRQoL,
all patients should have reported lower HRQoL at t1,
while this was only the case for patients who chose a
curative treatment, patients from the AS group even re-
ported (non-significant) improvements [37].
Table 1 Demographics
t0—no cancer
(N = 254)
t0—Pca
(N = 123)
t1—Pca
(N = 80)
Age at inclusion
≤ 65 years 106 (44%) 40 (33%) 24 (30%)
66–75 years 115 (48%) 73 (60%) 50 (63%)
≥ 76 years 20 (8%) 9 (7%) 5 (6%)
Education
Low 109 (43%) 48 (39%) 31 (39%)
Medium 60 (24%) 37 (30%) 25 (31%)
High 78 (31%) 36 (29%) 23 (29%)
Other/not specified 4 (2%) 2 (2%) 1 (1%)
Current occupation
Employed 70 (28%) 28 (23%) 15 (19%)
Not employed 183 (72%) 93 (77%) 64 (81%)
Partnership
Partner 224 (89%) 115 (94%) 74 (95%)
No partner 28 (11%) 7 (6%) 5 (6%)
Children
Yes 228 (91%) 118 (96%) 77 (96%)
No 24 (9%) 5 (4%) 3 (4%)
Prostate-specific antigen (PSA)
≤ 5 ng/ml 42 (17%) 19 (16%) 19 (25%)
5.01–10 ng/ml 125 (49%) 59 (48%) 37 (49%)
≥ 10.01 ng/ml 85 (34%) 44 (36%) 20 (26%)
Selected treatment
Active surveillance 26 (34%)
Radical prostatectomy 22 (29%)
Radiotherapy 28 (37%)
Numbers do not always add up to the same total due to item non-re-
sponse. Differences between groups did not reach statistical significance
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Earlier studies on physical and psychological outcomes in
Pca patients highlighted the perceived masculinity threat men
could experience [38, 39]. This threat affects how men cope
with their condition and the perceived threat could cause a
further decline of HRQoL after treatment. Although most of
the work on masculinity threats in Pca patients focused on
post-treatment outcomes, it is likely that this perceived threat
is already present from diagnosis onwards. In our results, re-
duced role functioning and increased sexual functioning
(compensatory behavior) could be indicative for the presence
of a masculinity threat [40, 41].
Personality factors
Optimism and decisional self-efficacy were associated
with better global health; this is in line with previous
research that found optimism and decisional self-efficacy
to be associated with less distress and better coping [21,
42]. In the current study, patients scoring higher on opti-
mism report better HRQoL prior to biopsy, when Pca was
suspected but not yet confirmed. After diagnosis, and a
treatment decision was required, optimism seemed to play
less of a role and decisional self-efficacy, the subjective
feeling of being able to take the right action, making good
decisions, and to ask questions, was positively associated
with HRQoL. This adds to previous findings about
knowledgeable (and therefore possibly more self-
efficated) patients reporting better HRQoL [43].
Instead of focusing on a single trait (e.g., neuroticism), this
study investigated a broader spectrum of the big five person-
ality traits. At t0, extraversion and neuroticism were related to
global health, while at t1, no relations were present anymore.
Hence, we found no evidence of a moderating role of specific
traits affecting changes in HRQoL. Another explanation could
be that the brief measure we used was not sensitive enough to
also detect statistically significant differences in the smaller t1
Table 2 HRQoL scores
No Pca Pca
t0 (N = 254) t0 (N = 123) t1 (N = 80)
HRQoL core Mean (SD) Mean (SD) Mean (SD) Mean difference (t1−t0)1
Global health 83.5 (14.8) 83.7 (15.4) 80.7 (16.1) − 3.0
Physical functioning 94.2 (10.4) 94.3 (10.1) 92.8 (12.7) −1.5
Role functioning 94.7 (14.9) 96.0 (12.9) 86.1 (24.2) − 9.9***
Emotional functioning 85.3 (16.0) 85.0 (16.8) 83.4 (19.9) − 1.6
Cognitive functioning 91.2 (15.0) 92.3 (12.5) 88.9 (16.9) − 3.4*
Social functioning 95.0 (13.9) 96.2 (10.1) 93.9 (14.3) − 2.3
Fatigue 11.4 (17.3) 10.7 (15.5) 17.0 (22.3) 6.3**
Nausea/vomiting 1.0 (4.7) 1.1 (5.2) 2.4 (11.9) 1.3
Pain 6.8 (15.8) 5.8 (12.6) 9.4 (19.8) 3.6
Dyspnoea 7.7 (16.9) 6.5 (15.3) 6.8 (17.3) 0.3
Insomnia 14.4 (23.8) 13.8 (21.5) 15.0 (25.6) 1.2
Appetite loss 1.9 (8.2) 2.0 (7.9) 4.7 (16.8) 2.7
Constipation 1.7 (8.0) 4.2 (12.7) 7.7 (20.0) 3.5*
Diarrhea 4.0 (13.4) 3.4 (11.0) 6.8 (18.9) 3.4
Financial difficulties 2.6 (12.3) 0.8 (5.3) 2.6 (12.9) 1.8
Prostate specific
Urinary symptoms 15.9 (13.4) 13.3 (11.8) 17.6 (15.6) 4.3*
Bowel symptoms 3.0 (6.3) 2.7 (5.8) 5.6 (10.5) 2.9**
Hormonal symptoms 3.5 (5.8) 3.8 (5.8) 7.0 (9.4) 3.2***
Sexual activity 63.1 (21.6) 61.5 (22.2) 65.4 (21.3) 3.9**
Sexual functioning 22.9 (20.3) 23.4 (19.6) 34.5 (24.0) 11.1*
All scales are 0–100; for functioning subscales, full functioning is represented by a score of 100; for symptoms,
absence of symptoms is represented by a score of 0. All comparisons at t0 between patients with and without
cancer were non-significant
1 Paired comparison t1 vs t0 (N = 70)
*p < 0.05
**p < 0.01
***p < 0.001
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sample. Future studies should use more extensive measures to
investigate this relation in more detail.
Study limitations
Some limitations need to be discussed. First, no detailed clin-
ical data about tumor stage was available, and PSAwas self-
reported by participants. However, patients were only eligible
for inclusion if Pca was suspected, following pre-biopsy
screening (rectal examination and PSA testing). Therefore,
we were still able to sample a homogeneous patient popula-
tion. And although we had no registration of the number of
patients refusing participation, the average Pca detection rate
in our sample was similar to what was expected based on
literature [5]. Secondly, dropout of men without Pca diagnosis
and non-response at t1 led to a limited number of patients per
treatment group available for further analyses. Moreover, the
comparison between t1 and t0 on group level had sufficient
power; however, the subgroup comparisons were lacking
power. As we found no statistically significant differences in
patient characteristics between responders and non-re-
sponders, we estimate the risk for selection bias was low.
Our results should therefore be seen as exploratory findings
on the development of HRQoL in Pca patients with a pre-
diagnosis baseline. Follow-up studies preferably use larger
samples.
Future studies
Based on the changes in HRQoLwe found in this study, future
studies should focus on determining the impact of the individ-
ual aspects of undergoing biopsy, receiving Pca diagnosis, and
selecting treatment. Compared to the current design, this
would require an additional measurement in between receiv-
ing diagnosis and making a treatment decision.
Table 3 HRQoL changes
grouped per treatment decision AS
N = 23
Curative treatment (RP or RT)
N = 38
t0
Mean (SD)
t1
Mean (SD)
t0
Mean (SD)
t1
Mean (SD)
HRQoL core
Global health 86.4 (15.8) 87.9 (10.5) 81.4 (14.4) 75.0 (18.8)
Physical functioning 93.9 (10.1) 94.2 (10.7) 93.3 (13.2) 92.3 (15.3)
Role functioning 97.0 (9.8) 97.0 (9.8) 95.5 (16.0) 79.7 (29.3)**
Emotional functioning 89.8 (14.5) 92.0 (13.0) 85.1 (17.7) 77.6 (23.7)*
Cognitive functioning 90.5 (13.5) 92.1 (10.2) 91.2 (12.1) 85.5 (20.9)*
Social functioning 93.1 (11.0) 99.2 (3.6)* 96.8 (8.6) 90.5 (18.7)*
Fatigue 10.1 (12.8) 8.6 (12.8) 10.5 (16.1) 21.6 (26.8)**
Nausea/vomiting 3.0 (8.4) 2.3 (5.9) 0 (0.0) 16.5 (2.7)
Pain 5.3 (14.9) 3.0 (8.4) 7.0 (14.3) 15.4 (25.8)
Dyspnoea 7.6 (14.9) 6.1 (16.7) 7.9 (19.7) 8.8 (20.0)
Insomnia 9.1 (15.2) 6.1 (16.7) 16.7 (24.2) 22.8 (31.1)
Appetite loss 4.5 (11.7) 1.5 (7.1) 2.6 (9.1) 8.8 (22.8)
Constipation 1.5 (7.1) 1.5 (7.1) 4.4 (13.8) 13.2 (26.3)*
Diarrhea 3.0 (9.8) 3.0 (9.8) 4.4 (11.4) 11.4 (24.8)
Financial difficulties 0.0 (0.0) 1.5 (7.1) 0.9 (5.4) 3.5 (17.0)
Prostate specific
Urinary symptoms 19.3 (12.9) 14.1 (10.4) 10.3 (8.7) 19.0 (18.4)**
Bowel symptoms 2.2 (6.3) 2.2 (4.5) 3.1 (5.2) 8.6 (13.4)*
Hormonal symptoms 3.9 (4.9) 5.6 (6.7) 3.0 (4.9) 6.4 (10.0)*
Sexual activity 60.9 (27.3) 63.0 (18.1) 58.6 (20.3) 68.0 (20.9)*
Sexual functioning 25.0 (17.9) 23.8 (19.6) 22.2 (16.4) 29.6 (18.4)
All scales are 0–100; for functioning subscales, full functioning is represented by a score of 100; for symptoms,
absence of symptoms is represented by a score of 0
AS active surveillance, RP radical prostatectomy, RT radiotherapy
*p < 0.05
**p < 0.01
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Furthermore, the current study did not follow up on pa-
tients with a negative biopsy result. To have a complete com-
parison of HRQoL after prostate biopsy, post-biopsy HRQoL
should also be compared between patients with a positive and
patients with a negative biopsy result. Recently, a prospective
study found similar HRQoL before and after diagnosis be-
tween Pca patients on AS and a non-cancer control group,
indicating HRQoL of patients on AS is similar to that of pa-
tients without cancer [44]. However, it would be interesting to
investigate if decisional self-efficacy is still associated with
HRQoL outcomeswhen no treatment decision has to bemade.
Clinical implications
This study emphasizes the impact of undergoing prostate bi-
opsy, receiving a Pca diagnosis, and selecting treatment.
Clinicians should be aware that optimism and decisional
self-efficacy are associated with HRQoL prior to treatment
onset. To ensure that optimism does not backfire post-treat-
ment, it is important to ensure accurate risk perceptions in
patients about the chances of treatment success and the occur-
rence of treatment side effects. Interventions to stimulate
shared decision-making, like decision aids, could be helpful
for achieving this, as well as to contribute to patients’ deci-
sional self-efficacy levels [45].
Conclusion
So far, most studies investigating HRQoL in Pca patients have
focused on the impact of treatment, while neglecting the psy-
chological burden caused by diagnosis and the treatment se-
lection process. This study showed that prior to treatment
onset, patients reported reduced functioning, more symptoms,
and lower overall global health, in particular if a curative
treatment was selected. During clinical counseling, managing
optimism when Pca is suspected (before and after biopsy) and
(decisional) self-efficacy when Pca is confirmed could help to
reduce the pre-treatment impact on HRQoL.
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